Novo Axes 9,000 Employees Worldwide as New CEO Makes Good on Cost Reallocation Promise
Novo Nordisk also lowered its full-year profit growth guidance in connection with the restructuring effort. The pharma now anticipates operating profit to grow from 4% to 10%, down from its prior projection of 10% to 16%.
Novo Axes 9,000 Employees Worldwide as New CEO Makes Good on Cost Reallocation Promise Read More »
